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bstract
The presence of mutations in specific regions of katG, inhA, oxyR–ahpC and kasA associated with isoniazid (INH)-resistant clinical isolates
f Mycobacterium tuberculosis from India were analysed by DNA sequencing. Point mutations in the katG gene at codon 315 and a mutation
t codon 138 were detected in 64.3% (45/70) and 4% (1/25) of isolates, respectively. Polymorphisms at codon 463 of the katG gene were
ound both in resistant and sensitive isolates. Mutation at the inhA and oxyR–ahpC promoter regions occurred in 11.4% (8/70) and 35.0%
14/40) of the isolates, respectively. No mutation was found to occur in kasA and inhA structural gene regions. Of the 70 resistant isolates
tudied, 55 (78.6%) showed mutation in the regions sequenced. This is the first comprehensive molecular analysis of INH resistance in India,
hich suggests that point mutation rather than deletion and insertion is the major cause of INH resistance.
2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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. Introduction
Tuberculosis (TB) remains a major public health prob-
em in many parts of the world, despite being a controllable,
reventable and curable disease. There were an estimated 8.8
illion TB cases in 2005, 7.4 million in Asia and sub-Saharan
frica. A total of 1.6 million people died of TB globally [1].
n India, one person dies from TB every minute [2], account-
ng for nearly 30% of TB cases in the world. The gravity
f the situation has further worsened due to the emergence
f multidrug-resistant TB (MDR-TB), i.e. strains resistant
o at least two of the first-line TB drugs isoniazid (INH)
nd rifampicin (RIF), extensive drug-resistant TB (XDR-
B), i.e. MDR-TB that is resistant to any fluoroquinolone
nd at least one of three injectable second-line drugs (capre-
mycin, kanamycin and amikacin), and HIV-TB. Acquisition
f resistance by the bacterium is a random event. In a given
ycobacterial population, the chance that a bacterium willcquire multidrug resistance is 10−14 (1 in 106 mutates to
evelop INH resistance and 1 in 108 mutates to develop
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IF resistance), thus isolates resistant to INH are seen with
ncreasing frequency [3].
INH is being extensively used as the frontline anti-TB drug
nd a choice for chemoprophylaxis. It is proposed that INH
nters the cell as a prodrug by passive diffusion and is acti-
ated by catalase–peroxidase, encoded by katG, to generate
ree radicals that transform INH into its active form [4]. Stud-
es have shown that inhA, encoding enoyl-acyl carrier protein
ACP) reductase, and kasA, encoding for ketoacyl-ACP syn-
hase, are the important intracellular targets for activated
NH. These enzymes are involved in elongation of fatty acids
ntermediate in the biosynthetic pathway [5,6]. In addition,
utations in the oxyR–ahpC intergenic region have been
dentified in INH-resistant isolates [7].
Reports from all over the world suggest that mutations
esponsible for INH resistance reside in katG, inhA, ahpC,
asA and other genes. Of these, three reports concerned
ndian isolates. Two of the reports lack information pertain-
ng to Ser315Thr substitution, a marker of INH resistance
8,9]. In the third study, information was given for 29 iso-
ates [10]. Therefore, a comprehensive molecular study is
equired that could provide a clear picture of the prevailing
esistance mechanisms for INH in India. Hence, the present
tudy was aimed at screening clinical isolates of Mycobac-
of Chemotherapy. All rights reserved.
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Table 1
Mutational profile of isoniazid-resistant Mycobacterium tuberculosis clini-
cal isolates in India
Strain no. (state)a Resistance katGb inhAc ahpC
1 (TN) MDR ATC
2 (TN) H
3 (TN) MDR ACC
4 (TN) H
5 (TN) H
6 (TN) MDR ACC
7 (TN) H ACC
8 (TN) MDR T → G, −34 bpd
G → A, −46 bp
9 (TN) MDR ACC
10 (TN) MDR ACC
11 (TN) MDR ACC
12 (TN) MDR ACC
13 (TN) H
14 (TN) H
15 (TN) MDR ACC
16 (TN) MDR
17 (TN) MDR AAC
18 (TN) H C → T
19 (TN) H AAC
20 (TN) MDR ACC
21 (TN) MDR ACC
22 (TN) H C → T
23 (TN) MDR ACC
24 (TN) MDR
25 (TN) H ACC
26 (TN) H ACC
27 (TN) H ACC
28 (TN) MDR
29 (AP) MDR ACC
30 (AP) H
31 (AP) H ACC
32 (AP) MDR G → A, −46 bp
33 (AP) MDR C → T
34 (AP) MDR ACC
35 (AP) MDR
36 (AP) MDR C → T
37 (AP) MDR ACC
38 (KA) H
39 (KA) H ACC C → T
40 (K) H ACC
41 (GU) MDR ACC G → A, −6 bp
42 (GU) H
43 (GU) H ACC T → A, −34 bp
44 (G) H ACC
45 (G) MDR ACC
46 (G) MDR ACC
47 (G) MDR ACC G → A, −6 bp
48 (A) MDR C → T, −30 bp
49 (TN) MDR
50 (TN) H
51 (TN) MDR AAC G → A, −46 bp
52 (TN) H ACC
53 (TN) H ACC G → A, −46 bp
54 (TN) H ACC
55 (TN) H ACC G → A, −46 bp2 A. Nusrath Unissa et al. / International Jo
erium tuberculosis in different regions of India, especially
outh India. It was shown that INH-resistant isolates from
outh India have low catalase activity [11]. Thus, it would be
f interest to determine the mutational pattern in the genes
ssociated with INH resistance from South Indian isolates.
. Material and methods
.1. Characterisation of M. tuberculosis clinical isolates
The study included 80 clinical isolates collected from the
uberculosis Research Centre. Ten isolates were sensitive to
NH and 70 isolates were INH-resistant (Table 1).
Drug sensitivity testing was performed using Lowenstein–
ensen medium, and INH sensitivity was determined by
he minimum inhibitory concentration (MIC) method. In
his study, isolates with three different MIC values of 1,
and >5 mg/L were considered resistant and isolates with
ICs ≤ 0.2 mg/L were considered sensitive.
Among the 70 resistant isolates, 40 were MDR strains
nd 30 were resistant to INH with or without resistance to
ther drugs. Complete resistance profiles were available for
8 of the 70 INH-resistant isolates. Of these 48 isolates,
he frequency of resistance to other drugs was as follows:
treptomycin, 19 (39.6%); RIF, 30 (62.5%); ethambutol, 18
37.5%); kanamycin, 6 (12.5%); ethionamide, 18 (37.5%);
nd ofloxacin, 12 (25.0%). The susceptibility profile for the
emaining 22 isolates with MIC ≥ 5 mg/L with respect to
ther drugs was not available.
.2. Preparation of DNA
Genomic DNA was prepared using sodium chloride and
etyltrimethylammonium bromide method as described pre-
iously [8].
.3. Ampliﬁcation of genes
Polymerase chain reaction (PCR) was performed with 30
ycles of amplification (1 min at 95 ◦C, 30 s at 60 ◦C and 1 min
t 72 ◦C). The primer sequences for the respective genes are
iven in Table 2. The amplicons were purified using a GFX
olumn (Amersham Biosciences Ltd., Little Chalfont, UK)
ccording to the manufacturer’s instructions.
.4. DNA sequencing and analysis
In this study, mutational analysis was performed in
hree structural regions of the katG gene spanning codons
10–200, 261–331 and 401–537, two regions (one regu-
atory and one structural) of the inhA gene, an intergenic
egion in oxyR–ahpC (Fig. 1) and a region from the
asA gene. Sequencing of the amplicons was carried
ut using an automated DNA sequencer (ABI Prism
10 Genetic Analyzer; Applied Biosystems, Foster City,
A). The data obtained were compared with sequences
56 (TN) MDR ACC
57 (TN) MDR ACC
58 (TN) H ACC
59 (TN) MDR C → T
60 (TN) MDR ACC G → A, −46 bp
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Table 1 (Continued )
Strain no. (state)a Resistance katGb inhAc ahpC
61 (TN) H AGCe G → A, −46 bp
62 (TN) MDR C → T, −30 bp
63 (TN) MDR ACC C → T
64 (TN) H ACC G → A, −46 bp
65 (TN) H ACC
66 (TN) H
67 (TN) MDR ACC C → T
68 (TN) MDR ACC
69 (TN) MDR ACC
70 (TN) MDR ACC
TN, Tamil Nadu; AP, Andhra Pradesh; KA, Karnataka; K, Kerala; GU,
Gujarat; G, Goa; A, Assam; MDR, multidrug resistance (strains resistant
to at least two of the first-line tuberculosis drugs isoniazid and rifampicin);
H, isoniazid-resistant isolates.
a TN strains (Nos. 1–28) and other state strains (Nos. 29–48) with mini-
mum inhibitory concentration (MIC) of 1 mg/L; strains with MIC of 5 mg/L
(Nos. 49–58) and >5 mg/L (Nos. 59–70).
b Substitution at codon 315.
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d Novel mutation.
e AAC to AGC at codon 138.
rom the EMBOSS database using the alignment tool
http://www.ebi.ac.uk/emboss/align). The GenBank acces-
ion numbers are X68081 for katG, U41388 for inhA, U16243
or ahpC and BX842579 for kasA.
. Results and discussion
.1. Mutational analysis in MDR and non-MDR
NH-resistant isolatesIn an effort to gain molecular insights into INH resis-
ance at the genomic level, a total of 80 samples comprising
0 resistant and 10 sensitive isolates, along with one M.
t
t
T
M
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rimers used in the study
enes (region) Primer sequences (5′–3′)
atG (S) F-C C G G C A C C T A C C G C A T C C A C
R-G C C C C A A T A G A C C T C A T C G G
atG (S) F-G A A A C A G C G G C G C T G G A T C G
R-G T T G T C C C A T T T C G T C G G G G
atG (S) F-C G A G G A A T T G G C C G A C G A G T
R-C G G C G C C G C G G A G T T G A A T G
nhA (R) F-C C T C G C T G C C C A G A A A G G G A
R-A T C C C C C G G T T T C C T C C G G T
nhA (S) F-T G C T C G A A C T C G A C G T G C A A
R-C G A A G C A T A C G A A T A C C G C C
hpC (R) F-A C C A C T G C T T T G C C G C C A C C
R-C C G A T G A G A G C G G T G A G C T G
asA (S) F-A T C G C G G C G T T C T C C A T G A
R-C G C G G G C G C C A C C A T A T
, structural; R, regulatory; F, forward; R, reverse.ig. 1. Schematic representation of sequenced regions, indicating the muta-
ions associated with isoniazid resistance identified in this study (with due
odification from [12]).
uberculosis H37Rv as control, were included in the muta-
ional analysis. None of the sensitive isolates had mutations.
he overall frequency of mutation was 87.5% (35/40) in
DR isolates and 66.7% (20/30) in non-MDR INH-resistant
Amplicon size (bp) Reference
269 [12]
T 209 [12]
T 414 [9]
A
248 [9]
209 [13]
G A
236 [14]
224 [14]
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solates. Twenty-five MDR isolates had Ser (AGC) to Thr
ACC), two isolates had Ser to Asn (AAC) and one iso-
ate had Ser to Ile (ATC) substitution at codon 315 in the
atG gene. Five of the isolates had C → T conversion at
osition −15 of inhA regulatory region. Of 8 isolates with
utation in the oxyR–ahpC intergenic region, three had
→ A at position −46, two had C → T at position −30,
wo had G → A at position −6 and one had T → G at
osition −34. Numbering of intergenic region nucleotides
s based on the position relative to the mRNA initiation
ite.
In the case of non-MDR INH-resistant isolates, 18 isolates
howed mutations in the katG gene (16 with ACC, one with
AC at codon 315 and one with AGC at codon 138). C → T
hanges were observed in three isolates in the inhA gene. Four
f the isolates had G → A at position −46 and one had T → A
t position −34 in oxyR–ahpC intergene region. Our study
ndicates the presence of a higher frequency of mutations in
DR compared with in non-MDR isolates.
.2. Relationship between drug susceptibility testing
nd mutational proﬁle
Differences were seen amongst the isolates with MIC val-
es of 1 mg/L and ≥5 mg/L (frequency of mutation 75%
s. 83%, respectively). In 22 isolates with high MIC val-
es of ≥5 mg/L, the mutation rate was 77% in katG, 13.6%
n inhA and 31.8% at the oxyR–ahpC locus. In contrast, in
he remaining 48 isolates with MIC values of 1 mg/L, the
utation rate was found to be 60% for katG, 10.4% for inhA
nd 12.5% for ahpC region, suggesting a strong correlation
etween the MICs of INH and the levels of mutation in our
solates.
Some differences in the distribution patterns of resistance
utations for the different states of India were detected, as
ndicated in Table 1.
.3. Determination of frequency of mutation at the
espective loci
Of the 70 phenotypically resistant isolates that were
equenced, 45 (64.3%) were found to be genotypically resis-
ant via katG mutations at codon 315 by the occurrence of
CC in 41 (58.6%), AAC in 3 (4.3%) and ATC in 1 (1.4%)
solates. Polymorphisms at codon 463 of katG gene were
ound in all (40 resistant and 10 sensitive) isolates.
A mutation at codon 138 having AAC → AGC conversion
as found in 1 of 25 isolates at the N-terminal region of the
atG gene, suggesting its role in the catalytic mechanism of
he katG protein, which is in accordance with the findings of
ouse et al. [15].
In this study, the observed frequency of mutation in the
pstream region of the inhA locus was ca. 11%. Interestingly,
ll mutations were of the same kind and were not in the other
ucleotides of the regulatory region as reported by others
12,13].
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The mutations identified in the structural part of inhA
esult in INH resistance due to a reduced binding affinity
f INH-NAD adduct for enoyl reductases [5]. The absence
f mutation Ser94Ala in the structural region of the inhA gene
n our study is in agreement with a report from Korea [13].
In 40 resistant isolates sequenced for the oxyR–ahpC
ntergenic region, various types of mutations, comprising of
ransversions (T → G and T → A at position −34) and tran-
itions (G → A at position −46, G → A at position −6 and
→ T at position −30) accounting to 35%, were found to
ccur. Instead of the common mutation T → C or A, a novel
utation with T → G transition at position −34 was found
n this study that, to the best of our knowledge, has not been
eported elsewhere in the literature.
No substitution was seen at codon 269 of the kasA struc-
ural region in 25 isolates and this mutation has been known
s a gene polymorphism that is unrelated to INH resistance.
study from Singapore has reported that mutation of kasA
oes not represent a frequent event associated with INH resis-
ance [16]. In the present study, lack of mutation in the kasA
ene suggests that this is a rare event associated with INH
esistance.
There were no occurrences of mutation in any of the
equenced regions in 15 of 70 INH-resistant clinical isolates,
uggesting the existence of other undefined mechanisms of
NH resistance in the phenotypically resistant isolates. Thus,
collective mutation frequency of 78.6% (55/70) is evident
n our isolates.
.4. Relative comparison between the sequenced regions
The frequency of mutations associated with INH resis-
ance was 65.7% in katG gene, 11.4% in inhA gene and
5% in oxyR–ahpC intergenic region. A relative compari-
on between the three loci in frequency distribution showed
hat 3 (4.3%) had mutations in katG and inhA, whereas 9
22.5%) had mutations in katG and ahpC. No isolates were
ound to have a mutation in both ahpC and inhA genes.
The findings from this study are consistent with previous
tudies of mutational patterns in INH resistance. The results
f our study suggest that point mutations appear to be the
ajor cause for INH resistance, in contrast to a study from
orth India where deletion and insertion were observed more
han substitution [9]. Our study also suggests the existence
f other undefined mechanisms of INH resistance in phe-
otypically resistant isolates that were not associated with
ny genotypic mutations. Hence, the genetic mechanism of
NH resistance in M. tuberculosis is highly complex involv-
ng several genes, and much remains to be explored to achieve
better understanding of the complex mechanism. Studies of
his kind will enable a better understanding of the molecular
echanisms of drug resistance, facilitating the develop-
ent of improved diagnostics to detect resistant organisms
apidly as well as providing insights into drug–target inter-
ctions to aid the rational design of more efficacious
rugs.
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